1.49
+0.1(+7.19%)
Currency In USD
| Previous Close | 1.39 |
| Open | 1.37 |
| Day High | 1.49 |
| Day Low | 1.36 |
| 52-Week High | 3.5 |
| 52-Week Low | 0.66 |
| Volume | 1.98M |
| Average Volume | 1.78M |
| Market Cap | 171.84M |
| PE | -1.02 |
| EPS | -1.46 |
| Moving Average 50 Days | 1.07 |
| Moving Average 200 Days | 1.18 |
| Change | 0.1 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $270.91 as of October 08, 2025 at a share price of $1.49. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $33.13 as of October 08, 2025 at a share price of $1.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
GlobeNewswire Inc.
Jun 11, 2025 1:00 PM GMT
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
GlobeNewswire Inc.
May 30, 2025 8:30 PM GMT
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies t
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
GlobeNewswire Inc.
May 28, 2025 9:54 PM GMT
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE)SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics,